Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 34HER2-positive Breast Cancer 5Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Meningeal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms by Site 1Metastatic Breast Cancer With a Isolated Brain Progression 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1Central Nervous System Diseases 1Breast Diseases 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage IA Breast Cancer AJCC v8 1

Interventions

tucatinib 1temsirolimus 1pembrolizumab 1niraparib 1lenvatinib 1atezolizumab 1Valproic Acid 1Trastuzumab 1Tissue Banks 1Sirolimus 1Immunoglobulin G 1Fulvestrant 1Doxycycline 1Disulfides 1Cetuximab 1Capecitabine 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × tucatinib × Breast × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡